

**Development of a New and Improved Guanidine-based Rac1 Inhibitor with in Vivo Activity against Non-Small Cell Lung Cancer**

Matías S. Ciarlantini<sup>a</sup>, Andrea Barquero<sup>b,c</sup>, Diana Wetzler<sup>b,c</sup>, Juan Bayo<sup>d</sup>, Martín M. Dodes Traian<sup>b,c</sup>, Hernán A. Bucci<sup>b,c</sup>, Esteban J. Fiore<sup>d</sup>, Lucía Gandolfi Donadio<sup>a,e</sup>, Lucas Defelipe<sup>b,c</sup>, Adrián Turjanski<sup>b,c</sup>, Javier A. Ramirez<sup>f,g</sup>, Guillermo Mazzolini<sup>d,h</sup>, Maria J. Comin<sup>\*a,e</sup>

<sup>a</sup> Departamento de Ingredientes Activos y Biorrefinerías, Instituto Nacional de Tecnología Industrial, Av. General Paz 5445, B1650WAB San Martín, Buenos Aires, Argentina

<sup>b</sup> Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires. Ciudad Universitaria, C1428EGA Ciudad Autónoma de Buenos Aires, Argentina

<sup>c</sup> Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) – Universidad de Buenos Aires. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN). Ciudad Universitaria, C1428EGA Ciudad Autónoma de Buenos Aires, Argentina

<sup>d</sup> Gene Therapy Laboratory, Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Austral, B1630FHB Derqui-Pilar, Argentina

<sup>e</sup> Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. General Paz 5445, B1650WAB San Martín, Buenos Aires, Argentina

<sup>f</sup> Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires. Ciudad Universitaria, C1428EGA Ciudad Autónoma de Buenos Aires, Argentina

<sup>g</sup> Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) – Universidad de Buenos Aires. Unidad de Microanálisis y Métodos Físicos Aplicados a Química Orgánica (UMYMFOR). Ciudad Universitaria, C1428EGA Ciudad Autónoma de Buenos Aires, Argentina

<sup>h</sup> Liver Unit, Hospital Universitario Austral, B1629AHJ Derqui-Pilar, Buenos Aires, Argentina

**KEYWORDS** Rac1 inhibitors, N,N'-disubstituted guanidines, protein-protein interaction inhibitors, lung cancer.

\* Corresponding Author

María Julieta Comin – Instituto nacional de Tecnología Industrial, Av. General Paz 5445, B1650WAB San Martín, Buenos Aires, Argentina; <http://orcid.org/0000-0003-2187-1932>;  
Phone: +54 911 4430 7859; Email: [jcomin@inti.gob.ar](mailto:jcomin@inti.gob.ar)

**ABSTRACT:** Rac1 (Ras-related C3 botulinum toxin substrate 1), is a member of the family of Rho GTPases involved in the dynamic control of cytoskeleton reorganization and other fundamental cellular functions including growth, motility and survival. Aberrant activity of Rac1 and its regulators is common in human cancer. In particular, deregulated expression/activity of Rac Guanine nucleotide Exchange Factors (GEFs), responsible for Rac activation, has been largely associated to a metastatic phenotype and drug resistance. Thus, the development of novel Rac1-GEF interaction inhibitors is a promising strategy for finding new preclinical candidates. In this work, we have studied structure-activity relationships within a new family of N,N'-

disubstituted guanidine as Rac1-GEF protein-protein interaction inhibitors, starting from our first developed member 1A-116. We found that new analogue 1D-142, bearing a pyridine ring instead of benzene ring, presents improved antiproliferative activity in human cancer cell lines and higher potency as Rac1-GEF interaction inhibitor in vitro. In addition, 1D-142 reduces TNF $\alpha$ -induced NF- $\kappa$ B nuclear translocation, a mechanisms mediated by Rac1 during cell proliferation and migration in NSCLC. Notably, 1D-142 was used to show for the first time the application of a Rac1 inhibitor in a lung cancer animal model.

## 1. INTRODUCTION

Rho family of small guanosine triphosphatases (Rho GTPases) are critical regulators of cellular functions that play important roles in cancer progression.<sup>1,2</sup> Between them, Rac GTPases (Rac1, Rac2, and Rac3) have been recognized as important nodes in signaling networks that control malignant transformation and the metastatic dissemination of cancer cells.<sup>3</sup> Particularly, most of the functions of the Ras-related C3 botulinum toxin substrate 1 (Rac1) such as the control of the actin cytoskeleton reorganization, cell proliferation, adhesion and migration are considered essential for tumor growth and dissemination.<sup>4</sup>

As most Rho GTPases, Rac1 acts as a molecular switch by cycling between inactive (GDP-bound) and active (GTP-bound) conformations. In their GTP-bound state, small GTPases bind effectors to activate biochemical responses. This cycle is tightly regulated by three main types of proteins: guanine nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs). The crucial step in Rac1 activation is the displacement of GDP by the action of GEFs, followed by binding to GTP normally present at

high cytosolic concentrations. Several other regulation mechanisms such as post-translational modifications or interactions with scaffold proteins add further complexity to Rac1 activity orchestration.<sup>5</sup>


Deregulation of Rho GTPase function in cancer is associated with fundamental hallmarks of progression, including changes in gene expression, cell survival, oncogenic transformation, tumor metabolism and invasiveness.<sup>6</sup> In this sense, Rac1 overexpression and/or hyperactivation has been reported in several cancers with high mortality rates, including prostate, bladder, gastric, liver, pancreatic, and lung cancer.<sup>2,7</sup> Additionally, a gain-of-function mutation named Rac1P29S, was found in a subset of melanomas, breast cancers and head and neck tumors.<sup>8</sup> Recently, it was found that Rac1 shows increased expression in lung cancer tissues compared with normal tissues and that its overexpression is associated with high tumor node metastasis (TNM) stage, and poor differentiation in non-small cell lung cancer (NSCLC) patients.<sup>9</sup> Besides, epidermal growth factor receptor (EGFR) activates Rac1 via inducing the accumulation of its specific GEF, T-cell lymphoma invasion and metastasis 1 (Tiam1), in NSCLC cells.<sup>10</sup> Despite these findings, there are not previous data exploring Rac1 inhibition as a potential therapeutic strategy for lung cancer treatment.

Rho GTPases have been previously considered "undruggable" due to their globular structure with limited small-molecule binding pockets and its high picomolar affinity for GTP or GDP binding combined with the micromolar levels of GTP available in cells.<sup>11,12</sup> However, in the last years, several strategies to achieve Rac1 inhibition have been developed. Between them, impairing the interaction of Rac1 with its GEFs has showed the highest success.<sup>13</sup> GEF-induced activation is the most common mechanism for signal-mediated GTPase activation. Frequently, this process is driven by aberrant signaling from growth factor receptors and/or GEFs

upregulation or mutation. In this regard, many GEFs present a relevant role in cancer and Rac1-GEF increased expression and/or activity appears to be a common phenomenon during cancer progression.<sup>11</sup> Therefore, targeting the Rac-GEF binding turns to be an appealing rational strategy to inhibit the GTPase activity and thus cancer invasion. In addition, the specific Rac1-GEF Tiam1 is crucial for cell-cell adhesion and cell migration. Numerous studies demonstrated that Tiam1-Rac signaling activation plays a crucial role in enhancing invasion and metastasis of various cancers.<sup>14</sup> Hence, several small molecules have been developed taking this particular protein-protein interaction (PPI) as molecular target by us<sup>15</sup> and others.<sup>16-18</sup>

The first reported selective inhibitor, NSC23766, was identified from a structure-based virtual screening of compounds that fitted into the surface groove of Rac1 critical for Tiam1 and Trio GEF interaction. In vitro, NSC23766 effectively inhibits Rac1 binding and activation by these Rac-specific GEFs in a concentration-dependent manner without interfering Cdc42 or RhoA activation. It also potently blocks serum or platelet-derived growth factor (PDGF)-induced Rac1 activation and lamellipodia formation.<sup>16</sup> Treatment of cells in culture with NSC23766 blocks invasion and metastasis of multiple different tumor types.<sup>19-21</sup> However, off-target effects in mouse platelets, such as receptor downregulation,<sup>22</sup> as well as the high IC<sub>50</sub> (~50 μmol/L) of NSC23766 make it ineffective for pharmacologic use. Therefore, several other new compounds were developed looking for more potent Rac1 inhibitors. Ferri and colleagues developed ZINC07949036 and compound **4**<sup>22</sup> with improved cellular activity.<sup>23</sup> Besides, further optimization of the chemical structure of NSC23766 led to the identification of better inhibitors, such as EHOp-016, which represents a highly potent Rac1 inhibitor with an IC<sub>50</sub> of 1.1 μM.<sup>18</sup> The efficacy of EHOp-016 has been subsequently validated in several cancer cell lines. However, its relatively high effective concentrations and its moderate bioavailability (~30% with t<sub>1/2</sub> of 4.5

hours) limited further development.<sup>24</sup> Therefore, additional optimization led to MBQ-167 one of the most potent Rac and Cdc42 inhibitor currently described in the literature. MBQ-167 inhibited Rac1/2/3 activity in the sub-micromolar range in vitro and in immunocompromised mouse models, MBQ-167 prevents mammary tumor progression 10-fold more potently than Ehop-016, although additional effects from an unknown alternate mechanism were also identified.<sup>25</sup>



**Figure 1.** Chemical structures of our previously identified guanidine-based Rac1 inhibitors.

In our previous work, a set of 200.000 drug-like known compounds from ZINC database was screened in silico in order to find candidates able to interact with Trp56 of Rac1, a residue that is known to be critical for GEF binding.<sup>26</sup> Using this approach, compound ZINC69391 (**1**) (Figure 1) was selected for in vitro evaluation showing a significant antiproliferative effect on several cancer cell lines. Moreover, taking this first-in-class guanidine-based Rac1 inhibitor as starting point, some exploratory chemical modifications yielded 1A-116 (**2**) as a second generation compound which displayed more potent activity in cancer cells and in vivo tumor mice models.<sup>15,27</sup> Additionally, 1A-116 showed selective pro-apoptotic activity in malignant glioma and in human acute leukemic human cell lines.<sup>28,29</sup> Furthermore, employing this analogue as biochemical tool, it was shown that Rac1-PAK1 axis inhibition restores tamoxifen sensitivity in

human resistant breast cancer cells. In this sense, 1A-116 effectively restored tamoxifen anti-proliferative effects and switched off PAK1 activity.<sup>30</sup>


A detailed computational study suggested that albeit both compounds show essentially the same interactions with the protein, a decrease of the free energy of solvation when the pyrimidine ring of ZINC69391 was replaced by a hydrophobic benzene ring in 1A-116 might account for a greater binding affinity of the later compound, thus leading to an increase in potency.<sup>15</sup>

Nevertheless, the high hydrophobicity of 1A-116 might impair its bioavailability, according to the widely accepted criteria for drug-like compound selection.

Here, we explore the chemical space surrounding ZINC69391 and 1A-116 and perform several in vitro and in vivo assays with the aim of finding a more potent and improved Rac1 inhibitor targeting the interaction with its activating protein Tiam1. In addition, we investigate for the first time the potential utilization of Rac1 inhibitors in vitro and in vivo for the treatment of non-small cell lung cancer.

## **2. RESULTS AND DISCUSSION**

**2.1. Design of the compounds.** Docking simulation studies showed that in both cases the guanidinium moiety present in ZINC69391 and 1A-116 interacts through four hydrogen bonds with Rac1 residues Ser71 and Asp57, positioning them in such a way that they can establish a hydrophobic interaction with key residue Trp56, known to be essential for Rac1-GEF binding (Figure 2).




**Figure 2.** Docked structure of 1A-116 on Rac1 Trp56-bearing surface cavity. It shows two double hydrogen bonds between the H-donor guanidine moiety and acceptors Asp57 and Ser71, and the  $\pi$ - $\pi$  stacking interaction between 3,5-dimethylphenyl group and Trp56 indole side chain. Additionally, 2-(trifluoromethyl)phenyl ring places into a hydrophobic region delimited by Val36, Tyr64 and Leu67 residues.

Thus, we designed a virtual library of N,N'-disubstituted guanidines where the trifluoromethylphenyl or pyrimidine ring were alternatively maintained while the other guanidine substituent was varied between either aliphatic, aromatic or heteroaromatic fragments, seeking to explore a wide region of the chemical space. Compounds were docked onto Rac1 Trp-56-bearing surface cavity and those who showed favorable binding energy were analyzed in terms of Lipinsky's and Veber's rules. Following this strategy a subset of nineteen new compounds was selected for synthesis (Figure 3A).



In order to gain further insight into the diversity of the library, we performed an additional chemoinformatic analysis in which 15 suitable molecular descriptors, meant to grasp the topological, structural and physicochemical properties of a set of compounds, were calculated (see SI file for details). These validated descriptors,<sup>31,32</sup> were taken as a base for a principal component analysis (PCA): the 15-dimension chemical space defined by these descriptors was projected onto 15 orthogonal axes (principal components), of which the first three (PC1, PC2 and PC3) allow to represent 77% of the initial variability of the data. Figure 3B shows a tridimensional biplot (PC1 vs PC2 and PC3) and the relative position of the selected compounds, whose spanning across the chemical space defined by the descriptors chosen for the analysis reflects the diversity of the library.



**Figure 3.** A) Chemical structures of top-scored potential Rac1 inhibitors selected by virtual screening. B) Three-dimensional biplot of principal component analysis (PCA). The relative


position of the selected compounds is displayed, along with the contribution of the selected descriptors, reflecting the diversity of the library.

**2.2. Chemistry.** The use of cyanamides as starting material for the preparation of guanidines is a well established methodology.<sup>33</sup> Thus, in order to synthesize compounds **3a-h** we obtained the pyrimidine-bearing cyanamide **5** following previously reported methods in gram scale.<sup>34</sup> With cyanamide **5** in hand, it was coupled with the corresponding amines (as hydrochlorides) to give the desired N,N'-disubstituted guanidines with yields ranging from 50 to 75% (Scheme 1A). Compound **4a** was prepared in a similar fashion employing 1,1,1-trifluoroacetylacetone for the synthesis of the corresponding cyanamide **6**.

Nevertheless, when the same approach was employed for generating the subset of compounds **4b-l**, we found that cyanamide **7**<sup>35</sup> failed to efficiently couple with all anilines. In this sense, it allowed us to prepare fair amounts of 2-trifluoromethylphenyl derivatives **4b-d** but it failed when employed for the introduction of sulfonamide-substituted or heteroaromatic anilines leading to complex mixtures of by-products. In addition, in our hands, the scale up of cyanamide **7** synthesis proved to be challenging, its isolation usually implicated long purification chromatographic procedures and irreproducible yields at increasing scales. Therefore, we explored a different synthetic strategy based on the use of EDCI as coupling agent. EDCI has been used previously as thiocarbonyl activating reagent for the synthesis of carbamoyl and acyl guanidines among others dialkylated guanidine derivatives in mild conditions.<sup>36,37</sup>

As shown in Scheme 1B, the synthesis of benzoylated thiourea **10** was accomplished in good yields by treatment of in situ generated isothiocyanate **8** with commercially available 2-

trifluoromethyl aniline (**9**). Coupling of **10** with the corresponding amines employing EDCI as desulfurizing agent led to the benzoyl-protected intermediates **11e-l** that, upon basic hydrolysis, afforded the desired products **4e-l** in variable fair to very good yields.



**Scheme 1.** A) Synthesis of 3,5-dimethyl pyrimidinyl derivatives (**3a-g**) and 2-trifluoromethyl phenyl derivatives (**4a-d**) employing cyanamides intermediates. B) EDCI-based synthesis of 2-trifluoromethyl phenyl derivatives **4e-l**


## 2.2. Biological Evaluation

### 2.2.1. Identification of new guanidine analogue 4i/1D-142 with more potent

antiproliferative effect by cell-based assays. A set of nineteen new compounds were

synthesized in order to explore the chemical space and optimize the biological activity of parent compounds ZINC69391 (**1**) and 1A-116 (**2**). Thus, to evaluate the antiproliferative profile of the new analogues, we selected a representative panel of five human cancer cell lines where Rac1 overexpression or hyperactivation has been associated with malignant transformation.<sup>37</sup> They include A549 (epithelial lung carcinoma), HT29 (epithelial colorectal adenocarcinoma), PC3 (prostate adenocarcinoma), A375 (epithelial skin melanoma) and MDA-MB-231 (epithelial breast adenocarcinoma). We performed a first set of experiments at a single dose of 50  $\mu$ M during 72 h using standard MTT assays (Figure 4). Strikingly, several new analogues such as compounds **3d**, **3g**, **4a**, **4e** and **4i** showed improved activity when compared to 1A-116. In particular, derivative **4i**, from now on 1D-142, showed the highest proliferation inhibition in all cell lines assayed, with  $IC_{50}$ 's ranging from 8 to 15  $\mu$ M.

As can be inferred from Table 1,  $IC_{50}$ s were 5 to 9-fold lower when compared to 1A-116. These results suggest a potential improvement of the Rac1 inhibitory activity by the newly identified analogue. Therefore, as 1D-142 proved to be the most potent compound from this series, it was selected for further studies.



**Figure 4.** Antiproliferative activity against a panel of representative five human cancer cell lines.

A) A549, HT29, PC3, A375 and MDA-MB-231 cells were treated with each compound at 50 μM for 72 h and cell viability was evaluated by MTT assay. The growth inhibition was quantified as percentages for the five cell lines. B) Dose-response curves for cell viability in each cell line treated with 4i/1D-142 or 1A-116 for 72 h using MTT assay. The IC<sub>50</sub> values were determined as described in the Experimental section. The results are reported as the mean ± standard deviation (SD) of three independent experiments.


**Table 1.** Biological data for compounds 1D-142 and 1A-116

Compound	IC <sub>50</sub> (μM) <sup>a</sup>				
	A549	HT29	PC3	A375	MDA-MB-231
1D-142	7.8 ± 0.4	9.0 ± 0.4	9.3 ± 0.3	7.4 ± 0.3	14.6 ± 0.4
1A-116	50 ± 2	83 ± 2	48 ± 1	51 ± 1	91 ± 2

<sup>a</sup>IC<sub>50</sub> = Drug concentration required to inhibit cell growth by 50%. Data are expressed as the mean ± SD from the dose-response curves of three independent experiments.

**2.2.3. Compound 1D-142 inhibited Tiam1-catalyzed GDP/GTP exchange of Rac1 by interfering with protein-protein interaction.** In order to verify if 1D-142 retains the ability of their parent compounds to interfere the Rac1-Tiam1 interaction, we developed a biochemical assay that allowed us to determine the inhibition of protein-protein complex formation. Thus, purified proteins were incubated with compound 1D-142 followed by complex affinity precipitation. The remaining Tiam1 concentration in the soluble fraction was measured by Western blotting showing higher levels in the presence of inhibitor 1D-142 when compared to the control. In addition, the effect was dose-dependent and stronger than that observed for compound 1A-116 (Figure 5A).


After confirming that 1D-142 inhibited Rac1-Tiam1 interaction, we tested its effect on Tiam1-catalyzed GDP/GTP exchange of Rac1. For this purpose, we performed an in vitro nucleotide exchange assay following mant-GTP fluorescence increase produced upon Rac1 activation. In agreement with previous results, we found that under physiologic levels of  $Mg^{2+}$ , Rac1 displays marginal mant-GTP loading but demonstrates rapid nucleotide exchange when Tiam1 was added.<sup>38</sup> The pre-incubation of Rac1 with increasing concentrations of 1D-142 showed that it inhibited Tiam1-induced nucleotide exchange in a dose dependent manner (Figure 5B and 5C).



**Figure 5.** Effect of 1D-142 on Rac1–Tiam1 interaction and on Tiam1-catalyzed GDP/GTP exchange of Rac1. A) His-Tiam1/GST-Rac1 complex was affinity-precipitated with glutathione agarose beads in the presence of 1D-142 (100 and 50  $\mu$ M) or 1A-116 (100  $\mu$ M). Control experiment corresponds to the complex in the absence of any compound. Western blot analysis of the supernatants was carried out with anti-His antibody. Densitometric values are shown below (arbitrary units). Bars represent the average of three experiments + SD. \* $p$ < 0.05 and \*\*\* $p$ < 0.001 1D-142 or 1A-116 vs Control by ANOVA. B) Representative fluorescence time trace in the presence of increasing concentrations of 1D-142 (100  $\mu$ M, red; 200  $\mu$ M, green; 500  $\mu$ M, orange). Time traces without 1D-142 (gray) and without Tiam1 (blue). C) Nucleotide exchange rates (k) for time traces showed in B. Bars represent the average of three experiments + SEM. \*\* $p$ < 0.01 and \*\*\* $p$ < 0.001 1D-142 or 1A-116 vs Control by ANOVA.

To understand the activity change between 1A-116 and 1D-142, we performed docking simulations over the crystal structure of Rac1. The structural difference between these two compounds resides in the transformation of the benzene ring to a pyridine ring. This change produces an increase in the predicted free energy of binding of 0.91 kcal/mol which could explain the observed difference in activity (See Supporting Info, Table S4). From a structural point of view, the change in energy can be pointed to the formation of an intramolecular hydrogen bond between the pyridine nitrogen and the guanidine moiety, which stabilizes the unfavorable high internal energy conformation for 1A-116 (+0.32 kcal/mol) into a more favorable one for 1D-142 (-0.71 kcal/mol). Nevertheless, other processes could also explain the observed differences like metabolism or membrane permeability. In this sense, it is interesting to note that a biplot of the aforementioned PCA analysis shows that 1D-142 lies between 1A-116

and ZINC69391 in the chemical space, alongside the principal components PC2, which has a significant contribution of the logD suggesting that hydrophobicity may also play a role in the modulation of biological properties, as discussed before (Figure 6).



**Figure 6.** Biplot of PC1 vs PC2 showing that the logD has a significant contribution to the relative position of compound 1D-142 in the chemical space when compared to ZINC69391 and 1A-116.

#### 2.2.4. In-vitro characterization of 1D-142 antitumoral effect on human non-small cell lung


**carcinoma (NSCLC) A549 cells.** As previously mentioned, Rac1 has emerged as an attractive molecular target for the development of new therapies for lung cancer. Moreover, Rac1 activation appears to be a compensatory mechanism that results in the emergence of resistance to current available treatments including gefitinib.<sup>39,40</sup> Considering that compound 1D-142 showed a potent antiproliferative activity in A549 lung cancer cell line, we conducted further



experiments to gain insight into the underlying mechanism of action. First, we tested if 1D-142 inhibited the clonogenic capability of A549 cells in vitro. This assay might be regarded as an indirect estimation of the anti-neoplastic effect of a compound.<sup>41</sup> As shown in Figure 7a, 1D-142 strongly reduced the number of A549 colonies in a dose response manner.

Recently, it has been reported that 1A-116 was able to induce apoptosis in patient-derived leukemic cells.<sup>29</sup> So, we wondered if the antitumoral effect observed for 1D-142 was due at least in part to apoptosis induction. A morphological analysis of dead cells showed that A549 cells treated for 24 h with 1D-142 exhibited apoptotic characteristics including nuclear condensation and fragmentation, cell shrinkage and fragmentation into apoptotic bodies, with respect to untreated cells in a dose dependent manner (Figure 7B).

It is well established that Rho small GTPases are key regulators of cell movement and actin cytoskeleton reorganization. Particularly, Rac1 is a key regulator of cell migration and lamellipodia formation in NSCLC cells.<sup>42</sup> In previous reports, it was shown that ZINC69391 was able to inhibit actin reorganization and cell migration of MDA-MB-231 and F3II cells.<sup>15</sup> Thus, we next studied the effect of compound 1D-142 on A549 cells migration using a wound healing assay under non-toxic conditions. As shown in Figure 7C cells treated with 1D-142 significantly reduced cell migration up to 90% compared to untreated control cells, suggesting an anti-metastatic potential. Therefore, we demonstrate that 1D-142 in vitro treatment in NSCLC cells results in decreased colony formation and cell migration and it induces apoptotic cell death program.




**Figure 7.** Antitumor effect of 1D-142 on A549 human non-small cell lung carcinoma cells. A) Clonogenic assay of A549 cells first treated with compound 1D-142 at indicated concentrations for 24 h and then cells were grown in drug-free medium for additional 7 days until visible colonies appeared. Representative photographs and percentage of colonies formed with respect to untreated control. Data are expressed as mean  $\pm$  SD of three independent experiments. \*\*\* $p < 0.001$  1D-142 vs Control by ANOVA B) Morphological analysis of cell death by DAPI staining. A549 cells were treated for 24 h with compound 1D-142 at the indicated doses. Representative fluorescence microscopy images taken at 400X and quantitative analysis of apoptotic cells. Results are presented as mean  $\pm$  SD of three separated experiments. \*\* $p < 0.01$  and \*\*\* $p < 0.001$  1D-142 vs Control by ANOVA. C) Wound healing assay of A549 cells in the presence or not of 1D-142. Representative photographs taken at 48 h and results expressed as percentage of wound closure of three independent experiments. \*\*\* $p < 0.001$  1D-142 vs Control by ANOVA.

**2.2.5. Compound 1D-142 abrogates TNF $\alpha$ -induced NF- $\kappa$ B nuclear translocation.** It was shown that cell proliferation and migration induced by Rac1 is mediated by NF- $\kappa$ B activation in

NSCLC.<sup>42</sup> Thus, we assessed if NF- $\kappa$ B activity was affected in A549 cells treated with 1D-142. NF- $\kappa$ B is a protein complex composed by two subunits sequestered in the cytoplasm in an inactive state by the inhibitory cytoplasmic binding protein I $\kappa$ B $\alpha$ .<sup>43</sup> Exposure of cells to various stimuli, such as TNF- $\alpha$ , leads to the rapid phosphorylation and proteolytic degradation of I $\kappa$ B $\alpha$ , which triggers RelA/p65 (the transcriptionally active subunit of the NF- $\kappa$ B heterodimer) translocation into the nucleus and initiates gene transcription. Remarkably, immunofluorescence microscopy showed that 1D-142 strongly inhibits the RelA/p65 translocation to the nucleus after TNF- $\alpha$  induction (Figure 8A).


Then, we wondered if the 1D-142 effect on RelA/p65 was mediated by the inhibition of I $\kappa$ B $\alpha$  degradation. Unexpectedly, pre-treatment with the same concentrations of 1D-142 that inhibited RelA/p65 translocation had no effect on TNF- $\alpha$ -induced I $\kappa$ B $\alpha$  degradation in whole A549 cell lysates (Figure 8B). Thus, these results indicate that 1D-142 abrogates TNF $\alpha$ -induced NF- $\kappa$ B activation through a mechanism that impedes RelA/p65 nuclear translocation but independently to I $\kappa$ B $\alpha$  degradation. Indeed, this finding may explain the previous observation that compound ZINC69391 decreases NF- $\kappa$ B transcriptional activity in human myeloid leukemia HL-60 cell line,<sup>29</sup> as well as the reduced TNF $\alpha$ -mediated NF- $\kappa$ B luciferase activity described in lung cancer cells treated with NSC23766.<sup>42</sup>



**Figure 8.** Effect of 1D-142 on A549 cells TNF $\alpha$ -induced NF- $\kappa$ B nuclear translocation. A549 cells were preincubated with 1D-142 at indicated concentrations for 24 h and then treated with TNF $\alpha$  (10 ng/ml) at 37 °C for 30 min. A) Cells were fixed and NF- $\kappa$ B nuclear translocation were visualized by immunofluorescence staining with anti-p65 antibodies. Nuclei were counterstained with DAPI. Magnification 400X. B) Cells were lysed and I $\kappa$ B $\alpha$  protein levels were analyzed by Western blot. Actin antibody was used as loading control.

**2.2.6. Compound 1D-142 inhibits human non-small cell lung carcinoma (NSCLC) A549 cell line tumor growth in vivo.** Finally, we wondered whether 1D-142 exerts anticancer effects in vivo. Strikingly, A549 tumor bearing mice treated with 1D-142 showed a marked reduction of

tumor growth in comparison with vehicle controls (Figure 9A). Even more, treatment with compound 1D-142 extended lifespan of tumor bearing mice to 95 days from the 63 days observed in the control mice group (Figure 9B). It should be noted, that treatment with 1D-142 did not adversely affected the weight of the mice during the experimental period (Figure 9C).



**Figure 9.** 1D-142 robustly reduces tumor volume in vivo and prolongs the survival of tumor bearing mice. Subcutaneous tumors generated from A549 cells were allowed to reach a volume of 50 mm<sup>3</sup>. Then, mice were treated every other day with vehicle (n=9) or 1D-142 10 mg/kg (n=9) until the end of the experiment. Graphs represent the tumor volume (A), percent survival (B) and the mice body weight (C). Error bars represent SEM. ns p>0.03, \*\*p< 0.01 and \*\*\*p< 0.001 1D-142 vs Vehicle (2-way ANOVA for tumor growth and mice weight, and Kaplan-Meier for survival). Median survival is indicated in the graph for percent survival.

### 3. CONCLUSIONS

In summary, we have achieved the exploration of the chemical space surrounding N,N'-disubstituted guanidines which are promising yet underexploited scaffolds for the design of new

Rac1 inhibitors. With the aid of computational tools, we generated a diverse library that was screened through a docking-based methodology, affording a set of compounds both energetically and conformationally promising. Selected compounds were synthesized and tested for antiproliferative activity on a panel of cancer cell lines, for which Rac1 overexpression or hyperactivation has been related to its aggressive phenotype. This led to the discovery of compound 1D-142 as a new guanidine-based inhibitor with a significantly higher potency both in vitro and in vivo than previously reported derivative 1A-116.

When compared to 1A-116, 1D-142 was consistently 5 to 9-fold more potent as antiproliferative agent in the five cell lines studied. By affinity precipitation and GDP/GTP exchange assays we showed that 1D-142 may inhibit Rac1 activation through the interference with Rac1-Tiam1 interaction in a concentration-dependent manner. We further studied the effect of 1D-142 on A549 NSCLC, a cell line that showed to be more resistant to treatment with our previously developed guanidine analogues. Remarkably, we found that treatment with 1D-142 not only inhibited the migration capability of A549 but also it was a strong pro-apoptotic inductor. Even more, 1D-142 treatment also reduced the TNF $\alpha$ -induced NF- $\kappa$ B nuclear translocation in NSCLC cells in a I $\kappa$ B $\alpha$  degradation independent manner. It is interesting to point out that the NF- $\kappa$ B pathway has been deeply related not only to Rac1 activity but also to lung carcinogenesis.<sup>42</sup> Indeed, 1D-142 showed significant antitumor efficacy in vivo in an A549 xenograft model by reducing tumor growth and increasing animal survival, with no decrease in mice body weight. Overall, our results suggest that 1D-142 is an appealing Rac1-Tiam1 interaction inhibitor for further development in the treatment of Non-Small Cell Lung Cancer.

## 4. EXPERIMENTAL SECTION

### 4.1. Chemistry

**General Procedures.** All chemical compounds were purchased from commercial sources or synthesized. All final products were at least 95% pure, as determined by  $^1\text{H}$  NMR. Reaction monitoring was performed on Merck silica gel 254F TLC plates. Column chromatography was performed on a Teledyne Isco CombiFlash  $\text{R}_f^+$  instrument under gradient elution conditions with RediSep disposable flash columns. Infrared spectra were recorded on a Nicolet iZ10 spectrometer. All melting points were determined on an Electrothermal IA9000 series digital melting point apparatus and are uncorrected.  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were carried out on Bruker Fourier 300, 300 MHz or Bruker Avance DPX 400, 400 MHz spectrometer using  $\text{CDCl}_3$ , MeOD or  $\text{DMSO-}d_6$  as the solvent and TMS as internal standard. High resolution positive ion electrospray ionization MS was conducted on a Waters Xevo G2S Q-TOF spectrometer operated at both positive and negative modes. Low resolution mass spectra were obtained either by EI on a Shimadzu QP2010 ultra spectrometer at ionization potential of 70 eV or by ESI on a Waters Quattro Premier XE spectrometer. Elemental analyses were measured with an Exeter Analytical CE-440 Elemental Analyzer and were within  $\pm 0.4\%$  of the theoretical values for C, H, and N. Elemental analyses were performed by UMYMFOR-CONICET. None of the tested compounds showed PAINS alerts.<sup>44</sup>

**N-(4,6-dimethylpyrimidin-2-yl)cyanamide (5).** Cyanamide **5** was synthesized as previously reported.<sup>34</sup>  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO-}d_6$ )  $\delta$  12.52 (br s, 1H, NH), 6.62 (s, 1H, H4), 2.30 (s, 6H,  $\text{CH}_3$ );  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO-}d_6$ )  $\delta$  166.8, 160.3, 115.9, 109.7, 21.9.

**N-(4-methyl-6-(trifluoromethyl)pyrimidin-2-yl)cyanamide (6).** To a suspension of cyanoguanidine (405 mg; 4.82 mmol) in water (3 ml) were added NaOH 2 N (0.22 ml) and 1,1,1-trifluoroacetylacetone (0.78 ml, 6.43 mmol) respectively, and refluxed until reaction was completed. After cooling the reaction to room temperature, 50 ml of CH<sub>2</sub>Cl<sub>2</sub> were added and the mixture was washed with brine (3 x 20 ml). The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The crude product was purified by silica gel flash column chromatography (Hex/AcOEt) to afford 328 mg (34 % yield) of 6 as a white solid. Mp: 176 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.25 (s, 1H, H4), 2.66 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>/MeOD): δ 172.1, 158.0, 155.8, 155.6 (q, *J* = 35.8 Hz), 120.2 (q, *J* = 274.8 Hz), 110.0, 24.4. IR (neat, cm<sup>-1</sup>): 2246 (CN), EI-MS *m/z* 202 (M<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M+H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>14</sub>F<sub>3</sub>N<sub>4</sub>O 221.0650; found 221.0666.

**N-(2-(trifluoromethyl)phenyl)cyanamide (7).** Cyanamide 7 was synthesized as previously reported.<sup>35</sup> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.63-7.59 (m, 2H, H3, H5), 7.45 (d, *J* = 8.6 Hz, 1H, H6), 7.22 (t, *J* = 7.8 Hz, 1H, H4), 6.23 (br s, 1H, NHCN). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 135.2, 133.9, 127.0 (q, *J* = 5.1 Hz), 123.8 (q, *J* = 270.7 Hz), 123.6, 117.4, 116.9 (q, *J* = 30.8 Hz) 109.7.

**N-((2-(trifluoromethyl)phenyl)carbamothioyl)benzamide (10).** Compound 10 was synthesized as previously reported.<sup>45</sup> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 12.54 (s, 1H, CONH), 9.22 (s, 1H, CSNH), 7.97 (d, *J* = 8.0 Hz, 1H, H3), 7.92 (d, *J* = 7.3 Hz, 2H, H2'), 7.74 (d, *J* = 7.8 Hz, 1H, H6), 7.68-7.62 (m, 2H, H4', H5), 7.55 (t, *J* = 7.9 Hz, 2H, H3'), 7.44 (t, *J* = 7.6 Hz, 1H, H4).

**General procedure A:** Synthesis of compounds 3a-g and 4a-d. A suspension of amine hydrochloride and the proper cyanamide (5, 6 or 7) in absolute ethanol was refluxed until reaction completion, monitored by TLC. Unless stated otherwise, after evaporation of the ethanol



under reduced pressure, water was added and the pH adjusted to 8-9 with NaOH 0.5 N. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (x5) and the organic phases were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure to give the crude product.

**4-(3-(4,6-dimethylpyrimidin-2-yl)guanidino)benzoic acid hydrochloride (3a).** Following general procedure A, 4-aminobenzoic acid hydrochloride (384 mg, 2.21 mmol) and **5** (327 mg, 2.21 mmol) were refluxed in absolute ethanol (6 ml). After cooling the reaction to room temperature, the solid was filtered and washed with cold ethanol to afford 436 mg (61 % yield) of **3a** as a white solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.17 (d, *J* = 8.3 Hz, 2H, H3'), 7.53 (d, *J* = 8.3 Hz, 2H, H2'), 7.09 (s, 1H, H4), 2.50 (s, 6H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, MeOD): δ 170.3, 168.8, 158.2, 155.4, 139.4, 132.7, 131.4, 125.9, 117.5, 23.6. IR (neat, cm<sup>-1</sup>): 2852 (COOH), 1601 (COOH). ESI-MS *m/z* 286 ([M+H]<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M+H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>16</sub>N<sub>5</sub>O<sub>2</sub> 286.1306; found 286.1313.

**1-(4,6-dimethylpyrimidin-2-yl)-3-o-tolylguanidine (3b).** Following general procedure A, o-toluidine hydrochloride (556 mg, 3.87 mmol) and **5** (572 mg, 3.86 mmol) were refluxed in absolute ethanol (4 ml) to give the desired compound. Purification of the crude product by silica gel flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH + 0.1 % TEA) afforded 699 mg (71 % yield) of **3b** as a white solid. Mp: 227-229 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.35 -7.30 (m, 4H, H3', H4', H5', H6'), 6.82 (s, 1H, H4), 2.44 (s, 6H, CH<sub>3</sub>), 2.38 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 168.4, 157.1, 154.5, 135.8, 132.1, 131.7, 129.2, 127.8, 126.9, 116.9, 23.9, 18.1. IR (neat, cm<sup>-1</sup>): 1654 (C=N), 1344 (N-C-N). EI-MS *m/z* 255 (M<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M+H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>5</sub> 256.1571; found 256.1562.

**1-(4,6-dimethylpyrimidin-2-yl)-3-isobutylguanidine (3c).** Following general procedure A, isobutylamine hydrochloride (2.038 g, 18.59 mmol) and **5** (274 mg, 1.85 mmol) were refluxed in absolute ethanol (8 ml) to give the desired compound. Purification of the crude product by recrystallization from ethyl acetate/methanol afforded 307 mg (75 % yield) of **3c** as a white solid. Mp: 172 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.66 (s, 1H, H4), 3.38 (d, *J* = 6.6 Hz, 2H, H1'), 2.34 (s, 6H, CH<sub>3</sub>), 1.99 (m, 1H, H2'), 1.01 (d, *J* = 6.7 Hz, 6H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 167.9, 158.3, 155.2, 115.0, 49.5, 28.0, 23.9, 20.1. IR (neat, cm<sup>-1</sup>): 1637 (C=N). EI-MS *m/z* 221 (M<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M+H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>20</sub>N<sub>5</sub> 222.1719; Found 222.1732.

**1-(4,6-dimethylpyrimidin-2-yl)-3-(3-nitrophenyl) guanidine hydrochloride (3d).** Following general procedure A, 3-nitroaniline (188 mg, 1.36 mmol) and **5** (206 mg, 1.39 mmol) were refluxed in absolute ethanol (3.5 ml). After cooling the reaction to room temperature, the solid was filtered and washed with cold ethanol to afford 272 mg (62 % yield) of **3d** as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ 8.28 (t, *J* = 2.0 Hz, 1H, H2'), 8.21 (d, *J* = 8.3 Hz, 1H, H6'), 7.89 (d, *J* = 7.5 Hz, 1H, H4'), 7.78 (t, *J* = 8.1 Hz, 1H, H5'), 7.13 (s, 1H, H4), 2.45 (s, 6H, CH<sub>3</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>): δ 168.4, 156.5, 154.0, 148.4, 135.8, 131.9, 131.2, 121.9, 120.3, 116.1, 23.2. IR (neat, cm<sup>-1</sup>): 1475 (NO<sub>2</sub>), 1340 (NO<sub>2</sub>). ESI-MS *m/z* 287 ([M+H]<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M+H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>15</sub>N<sub>6</sub>O<sub>2</sub> 287.1256; found 287.1268.

**1-(4,6-dimethylpyrimidin-2-yl)-3-propylguanidine (3e).** Following general procedure A, propylamine hydrochloride (1.745 g, 18.26 mmol) and **5** (301 mg, 2.03 mmol) were refluxed in absolute ethanol (8 ml) to give the desired compound. Purification of the crude product by recrystallization from acetonitrile afforded 300 mg (71 % yield) of **3e** as a white solid. Mp: 196-197 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.40 (s, 1H, H4), 3.24 (t, *J* = 6.9 Hz, 2H, H2'), 2.32 (s, 6H, CH<sub>3</sub>), 1.63 (m, *J* = 7.2 Hz, 2H, H2'), 0.97 (t, *J* = 7.2 Hz, 3H, H3'). <sup>13</sup>C NMR (100 MHz,

CDCl<sub>3</sub>):  $\delta$  166.4, 166.2, 158.3, 110.8, 43.1, 24.0, 22.8, 11.5. IR (neat, cm<sup>-1</sup>): 1525 (C=N), 1331 (N-C-N). EI-MS *m/z* 207 (M<sup>+</sup>). Elemental analysis for C<sub>10</sub>H<sub>17</sub>N<sub>5</sub> · 0.1 H<sub>2</sub>O calcd, %C, 57.45, %H, 8.29, %N, 33.50; found: %C, 57.12, %H, 8.20, %N, 33.85.

**1-(4,6-dimethylpyrimidin-2-yl)-3-(2-propylphenyl) guanidine (3f).** Following general procedure A, 2-propylaniline hydrochloride (194 mg, 1.13 mmol) and **5** (167 mg, 1.13 mmol) were refluxed in absolute ethanol (4 ml) to give the desired compound. Purification of the crude product by recrystallization from water/acetonitrile afforded 223 mg (70 % yield) of **3f** as a white solid. Mp: 132 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.25 (d, *J* = 7.3 Hz, 1H, H3'), 7.20 (t, *J* = 7.3 Hz, 1H, H5'), 7.10 (m, 2H, H6', H4'), 6.50 (s, 1H, H4), 2.59 (t, *J* = 7.4 Hz, 2H, CH<sub>2</sub>-A), 2.33 (s, 6H, CH<sub>3</sub>), 1.60 (m, 2H, CH<sub>2</sub>-B), 0.93 (t, *J* = 7.3 Hz, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  167.0, 162.9, 152.7, 141.1, 137.8, 130.3, 126.9, 124.8, 112.1, 33.9, 24.0, 23.6, 14.2. IR (neat, cm<sup>-1</sup>): 1655 (C=N). ESI-MS *m/z* 284 ([M+H]<sup>+</sup>). Elemental analysis for C<sub>16</sub>H<sub>21</sub>N<sub>5</sub>: calcd, %C, 67.82; %H, 7.47; %N, 24.71; found, %C, 67.68; %H, 7.68; %N, 24.52.

**1-(cyclohexylmethyl)-3-(4,6-dimethylpyrimidin-2-yl) guanidine (3g).** Following general procedure A, cyclohexanemethylamine hydrochloride (2.691 g, 17.98 mmol) and **5** (296 mg, 2.00 mmol) were refluxed in absolute ethanol (9 ml) to give the desired compound. Purification of the crude product by recrystallization from acetonitrile afforded 260 mg (50 % yield) of **3g** as a white solid. Mp: 236-238 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  6.42 (s, 1H, H4), 3.05 (d, *J* = 6.6 Hz, 2H, H1'), 2.32 (s, 6H, CH<sub>3</sub>), 1.68-1.84 (m, 5H, H3'A, H4'A, H5'A), 1.59 (m, 1H, H2'), 1.13-1.32 (m, 3H, H4'B, H5'B), 0.96-1.07 (m, 2H, H3'B). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  166.4, 165.6, 158.5, 110.9, 48.0, 37.8, 30.9, 26.3, 25.8, 23.8. IR (neat, cm<sup>-1</sup>): 1523 (C=N), 1332 (N-C-N). EI-MS *m/z* 261 (M<sup>+</sup>). Elemental analysis for C<sub>14</sub>H<sub>23</sub>N<sub>5</sub> · 0.1 H<sub>2</sub>O: calcd, %C, 63.90, %H, 8.89, %N, 26.61; found %C, 64.10, %H, 8.89, %N, 26.27.

**1-(4-methyl-6-(trifluoromethyl)pyrimidin-2-yl)-3-(2-(trifluoromethyl)phenyl)guanidine**

**(4a).** Following general procedure A, 2-(trifluoromethyl)aniline hydrochloride (192 mg, 0.97 mmol) and **6** (197 mg, 0.97 mmol) were refluxed in absolute ethanol (3 ml) to give the desired compound. Purification of the crude product by silica gel flash column chromatography (Hex/AcOEt + 0.1 % TEA) afforded 81 mg (23 % yield) of **4a** as a white solid. Mp: 135-136 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.67 (d, *J* = 7.8 Hz, 1H, H3'), 7.51 (t, *J* = 7.6 Hz, 1H, H5'), 7.19 -7.17 (m, 2H, H4', H6'), 6.96 (s, 1H, H4), 2.43 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.2, 160.1, 155.1 (q, *J* = 36.0 Hz), 150.0, 145.9, 132.8, 127.0 (q, *J* = 5.1 Hz), 125.5, 124.5 (q, *J* = 29.6 Hz), 124.0 (q, *J* = 271.6 Hz), 123.2, 120.3 (q, *J* = 273.4 Hz), 108.5, 24.3. IR (neat, cm<sup>-1</sup>): 1668 (C=N), 1316 (N-C-N). EI-MS *m/z* 363 (M<sup>+</sup>). Elemental analysis for C<sub>14</sub>H<sub>11</sub>F<sub>6</sub>N<sub>5</sub>: calcd %C, 46.29, %H, 3.05, %N, 19.28; found %C, 46.18, %H, 2.96, %N, 18.89.

**1-*o*-tolyl-3-(2-(trifluoromethyl)phenyl)guanidine (4b).** Following general procedure A, *o*-toluidine hydrochloride (118 mg; 0.82 mmol) and **7** (153 mg; 0.82 mmol) were refluxed in absolute ethanol (2.5 ml) to give the desired compound. Purification of the crude product by silica gel flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH + 0.1 % TEA) afforded 130 mg (54 % yield) of **4b** as a white solid. Mp: 129 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.61 (d, *J* = 7.7 Hz, 1H, H3), 7.44 (t, *J* = 7.5 Hz, 1H, H5), 7.28 (d, *J* = 7.6 Hz, 1H, H6'), 7.23 -7.05 (m, 5H, H3', H4, H4', H5, H6), 2.27 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 149.6, 147.6, 137.4, 134.0, 132.9, 131.2, 127.1, 127.0 (q, *J* = 5.1 Hz), 126.2, 126.1, 125.3, 124.5 (q, *J* = 271.3 Hz), 123.9 (q, *J* = 29.1 Hz), 122.2, 17.9. IR (neat, cm<sup>-1</sup>): 1645 (C=N), 1316 (N-C-N). EI-MS *m/z* 293 (M<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M+H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>15</sub>F<sub>3</sub>N<sub>3</sub> 294.1218; found 294.1235.

**1-phenyl-3-(2-(trifluoromethyl)phenyl)guanidine (4c).** Following general procedure A, aniline hydrochloride (97 mg, 0.75 mmol) and **7** (138 mg, 0.74 mmol) were refluxed in absolute ethanol

(2.5 ml) to give the desired compound. Purification of the crude product by silica gel flash column chromatography (Hex/AcOEt + 0.1 % TEA) afforded 137 mg (66 % yield) of **4c** as a white solid. Mp: 108-109 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.62 (d, *J* = 7.5 Hz, 1H, H3), 7.44 (t, *J* = 7.2 Hz, 1H, H5), 7.29 (t, *J* = 7.2 Hz, 2H, H3'), 7.22 (d, *J* = 7.0 Hz, 2H, H2'), 7.08 (br d, 3H, H4, H6, H4'), <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 149.2, 147.1, 139.5, 132.9, 129.5, 127.0 (q, *J* = 5.1 Hz), 125.3, 124.4 (q, *J* = 271.4 Hz), 124.3, 123.9 (q, *J* = 29.0 Hz), 122.6, 122.5. IR (neat, cm<sup>-1</sup>): 1647 (C=N), 1318 (N-C-N). EI-MS *m/z* 279 (M<sup>+</sup>). Elemental analysis for C<sub>15</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O • 0.25 H<sub>2</sub>O: calcd, %C, 59.26, %H, 4.44, %N, 14.81, found: %C, 59.68, %H, 4.14, %N, 14.42.

**1-(3-nitrophenyl)-3-(2-(trifluoromethyl)phenyl)guanidine (4d).** Following general procedure A, 3-nitroaniline hydrochloride (72 mg, 0.41 mmol) and **7** (100 mg, 0.54 mmol) were refluxed in absolute ethanol (2.5 ml) to give the desired compound. Purification of the crude product by silica gel flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) afforded 81 mg (61 % yield) of **4d** as a white solid. Mp: 146 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/MeOD): δ 8.47 (s, 1H, H2'), 7.83 -7.78 (m, 2H, H4', H6'), 7.63 (d, *J* = 7.8 Hz, 1H, H3), 7.47 (t, *J* = 7.7 Hz, 1H, H5), 7.42 (t, *J* = 8.2 Hz, 1H, H5'), 7.13 -7.10 (m, 2H, H4, H6). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>/MeOD): δ 148.6, 148.5, 146.4, 142.2, 132.5, 129.1, 126.4 (q, *J* = 5.2 Hz), 125.4, 124.6, 124.1 (q, *J* = 271.1 Hz), 123.3 (q, *J* = 29.3 Hz), 122.2, 116.1, 114.1. IR (neat, cm<sup>-1</sup>): 1656 (C=N), 1520 (N-O), 1318 cm<sup>-1</sup> (N-C-N). EI-MS *m/z* 324 (M<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M+H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>12</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> 325.0912; found 325.0931.

**General procedure B:** Synthesis of compounds **4e-l**. To a solution of the corresponding amine and benzoyl thiourea **10** in anhydrous CH<sub>2</sub>Cl<sub>2</sub>, triethylamine and EDCI were respectively added at 0 °C. The reaction mixture was stirred under Argon atmosphere. After 1 hour the ice bath was removed and the solution was stirred over night at room temperature. After completion of the

reaction assessed by TLC, the mixture was washed with 1% HCl (x2), water and brine. Organic phase was dried and evaporated under reduced pressure. The residue was dissolved in MeOH and 10% NaOH solution was added. The mixture was vigorously stirred at 80°C for 1.5 hours and cooled to room temperature before extraction with AcOEt (x3). The organic phases were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the solvent was removed to give the desired crude product.

**1-(pyridin-2-yl)-3-(2-(trifluoromethyl)phenyl)guanidine (4e).** Following general procedure B, 2-aminopyridine (50 mg, 0.53 mmol), **10** (123 mg, 0.38 mmol), TEA (0.07 mL, 0.50 mmol) and EDCI (207 mg, 1.08 mmol) in 6.5 mL CH<sub>2</sub>Cl<sub>2</sub> afforded 34 mg (32 % yield) of **4e** as a white solid after recrystallization from methanol. Mp: 136 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.13 (d, *J* = 4.4 Hz, 1H, H3'), 7.64 (d, *J* = 7.6 Hz, 1H, H3), 7.52 (t, *J* = 7.5 Hz, 1H, H5'), 7.47 (t, *J* = 7.6 Hz, 1H, H5), 7.11 (d, *J* = 8.1 Hz, 1H, H6'), 7.10 (t, *J* = 8.9 Hz, 1H, H4), 6.83 (t and br s overlapped, *J* = 6.0 Hz, 3H, H4', NH), 6.59 (d, *J* = 8.2 Hz, 1H, H6). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 154.8, 151.5, 146.1, 138.3, 132.9, 127.1 (q, *J* = 5.3 Hz), 125.8, 124.7 (q, *J* = 29.3 Hz), 124.1 (q, *J* = 271.3 Hz), 123.1, 116.6, 112.8. IR (neat, cm<sup>-1</sup>): 1660 (C=N). EI-MS *m/z* 280 (M<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M-H]<sup>-</sup> calcd for C<sub>15</sub>H<sub>16</sub>N<sub>5</sub>O<sub>2</sub> 279.0858; found 279.0866.

**4-(3-(2-(trifluoromethyl)phenyl)guanidino)benzenesulfonamide (4f).** Following general procedure B, 4-aminobenzene sulfonamide (219 mg, 1.27 mmol), **10** (414 mg, 1.28 mmol), TEA (0.17 mL, 1.22 mmol) and EDCI (491 mg, 2.56 mmol) in 10 mL CH<sub>2</sub>Cl<sub>2</sub> afforded 86 mg (20 % yield) of **4f** as a white solid after silica gel flash column chromatography purification (Hex/AcOEt). Mp: 174 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/MeOD): δ 7.78 (d, *J* = 8.6 Hz, 2H, H3'), 7.63 (d, *J* = 8.4, 3H, H3, H2'), 7.48 (t, *J* = 7.6 Hz, 1H, H5), 7.12 (t, *J* = 7.6 Hz, 1H, H4), 7.09 (d, *J* = 7.6 Hz, 1H, H6). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>/MeOD): δ 148.3, 146.5, 144.6, 134.6, 132.5,

126.8, 126.4 (q,  $J = 4.9$  Hz), 124.4, 124.0 (q,  $J = 270.9$  Hz), 123.1 (q,  $J = 29.3$  Hz), 122.1, 118.6.

IR (neat,  $\text{cm}^{-1}$ ): 1652 (C=N), 1148 ( $\text{SO}_2$ ). EI-MS  $m/z$  358 ( $\text{M}^+$ ). HRMS (ESI/QTOF)  $m/z$ :

$[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{14}\text{H}_{14}\text{F}_3\text{N}_4\text{O}_2\text{S}$  359.0789; found 359.0799.

**1-(pyridin-3-yl)-3-(2-(trifluoromethyl)phenyl)guanidine (4g).** Following general procedure B, 3-aminopyridine (54 mg, 0.57 mmol), **10** (116 mg, 0.36 mmol), TEA (0.07 mL, 0.50 mmol) and EDCI (208 mg, 1.09 mmol) in 6.5 mL  $\text{CH}_2\text{Cl}_2$  afforded 68 mg (67 % yield) of **4g** as a white solid after recrystallization from water/methanol. Mp: 177 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3/\text{MeOD}$ ):  $\delta$  8.36 (s, 1H, H2'), 8.23 (br s, 1H, H6'), 8.12 (d,  $J = 4.1$  Hz, 1H, H4'), 7.63 (d,  $J = 7.8$  Hz, 1H, H3), 7.46 (t,  $J = 7.5$  Hz, 1H, H5), 7.25 (dd,  $J_1 = 8.2$  Hz,  $J_2 = 4.8$  Hz, 1H, H5'), 7.10 (m, 2H, H4, H6).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3/\text{MeOD}$ ):  $\delta$  148.5, 146.5, 142.3, 140.8, 138.3, 132.8, 127.8, 126.8 (q,  $J = 5.2$  Hz), 124.7, 124.3 (q,  $J = 271.0$  Hz), 124.0, 123.6 (q,  $J = 28.9$  Hz), 122.4. IR (neat,  $\text{cm}^{-1}$ ): 1668 (C=N). EI-MS  $m/z$  280 ( $\text{M}^+$ ). HRMS (ESI/QTOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{13}\text{H}_{12}\text{F}_3\text{N}_4$  281.1014; found 281.1017.

**N-methyl-3-(3-(2-(trifluoromethyl)phenyl)guanidino) benzenesulfonamide (4h).** Following general procedure B, 3-amino-N-methylbenzenesulfonamide hydrochloride (144 mg, 0.65 mmol), **10** (221 mg, 0.68 mmol), TEA (0.20 mL, 1.44 mmol) and EDCI (282 mg, 1.47 mmol) in 3.5 mL  $\text{CH}_2\text{Cl}_2$  afforded 105 mg (43 % yield) of **4h** as a white-yellow solid after silica gel flash column chromatography purification ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$ ). Mp: 79-80 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.82 (d,  $J = 7.1$  Hz, 1H, H4'), 7.74 (s, 1H, H2'), 7.63 (d,  $J = 7.7$  Hz, 1H, H3), 7.47-7.38 (m, 3H, H5, H6', H5'), 7.12 (t,  $J = 7.6$  Hz, 1H, H4), 7.08 (d,  $J = 7.9$  Hz, 1H, H6), 2.59 (s, 3H,  $\text{CH}_3$ ).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  148.9, 146.0, 141.7, 139.0, 132.9, 129.6, 126.8 (q,  $J = 5.1$  Hz), 125.1, 124.3, 124.3 (q,  $J = 271.3$  Hz), 123.7 (q,  $J = 29.0$  Hz), 122.8, 120.7, 118.1, 29.1.

IR (neat,  $\text{cm}^{-1}$ ): 1647 (C=N), 1154 ( $\text{SO}_2$ ). EI-MS  $m/z$  372 ( $\text{M}^+$ ). HRMS (ESI/QTOF)  $m/z$ :

$[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{15}\text{H}_{16}\text{F}_3\text{N}_4\text{O}_2\text{S}$  373.0946; found 373.0959.

**1-(4,6-dimethylpyridin-2-yl)-3-(2-(trifluoromethyl)phenyl)guanidine (4i/1D-142).** Following general procedure B, 4,6-dimethyl-2-aminopyridine (1,43 g; 11,69 mmol), **10** (2,51 g; 7,75 mmol), TEA (1,53 mL; 10,76 mmol) and EDCI (4,45 g; 23,21 mmol) in 100 mL  $\text{CH}_2\text{Cl}_2$  afforded 1.91 g (80 % yield) of **4i** as a white solid after recrystallization from water/methanol.

Mp: 183 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.65 (d,  $J = 7.7$  Hz, 1H, H3), 7.50 (t,  $J = 7.6$  Hz, 1H, H5), 7.19 (d,  $J = 7.9$  Hz, 1H, H6), 7.12 (t,  $J = 7.6$  Hz, 1H, H4), 7.03 (br s, NH), 6.37 (s, 1H, H4'), 5.77 (s, 1H, H6'), 2.29 (s, 3H,  $\text{CH}_3$  A), 1.86 (s, 3H,  $\text{CH}_3$  B).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  154.6, 154.3, 151.7, 149.2, 148.2, 132.8, 127.1 (q,  $J = 5.2$  Hz), 126.2, 125.2 (q,  $J = 28.9$  Hz), 124.2 (q,  $J = 271.5$  Hz), 122.3, 116.6, 109.5, 24.0, 20.7. IR (neat,  $\text{cm}^{-1}$ ): 1658 (C=N). EI-MS  $m/z$  308 ( $\text{M}^+$ ). HRMS (ESI/QTOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{15}\text{H}_{16}\text{F}_3\text{N}_4$  309.1327; found 309.1336.

**1-(3,4-dimethylisoxazol-5-yl)-3-(2-(trifluoromethyl)phenyl)guanidine (4j).** Following general procedure B, 5-amino-3,4-dimethylisoxazole (65 mg, 0.58 mmol), **10** (114 mg, 0.35 mmol), TEA (0.07 mL, 0.50 mmol) and EDCI (148 mg, 0.77 mmol) in 6.5 mL  $\text{CH}_2\text{Cl}_2$  afforded 28 mg (27 % yield) of **4j** as a white solid after recrystallization from water/methanol. Mp: 158 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3/\text{MeOD}$ ):  $\delta$  7.81 (d,  $J = 7.8$  Hz, 1H, H6), 7.67 (d,  $J = 7.8$  Hz, 1H, H3), 7.58 (t,  $J = 7.6$  Hz, 1H, H5), 7.30 (t,  $J = 7.7$  Hz, 1H, H4), 2.15 (s, 3H,  $\text{CH}_3$  A), 1.83 (s, 3H,  $\text{CH}_3$  B).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3/\text{MeOD}$ ):  $\delta$  165.8, 161.2, 151.2, 135.7, 132.5, 127.2, 126.4 (q,  $J = 5.1$  Hz), 125.1, 123.5 (q,  $J = 271.0$  Hz), 123.5 (q,  $J = 29.1$  Hz), 97.0, 10.3, 6.1. IR (neat,  $\text{cm}^{-1}$ ): 1642 (C=N). EI-MS  $m/z$  298 ( $\text{M}^+$ ). HRMS (ESI/QTOF)  $m/z$ :  $[\text{M}+\text{H}]^+$  calcd for  $\text{C}_{13}\text{H}_{14}\text{N}_4\text{O}$  299.1120; found 299.1127.



**N,N-dimethyl-2-(3-(2-(trifluoromethyl)phenyl)guanidino)benzenesulfonamide (4k).**

Following general procedure B, 2-amino-N,N-dimethylbenzenesulfonamide hydrochloride (225 mg, 0.95 mmol), **10** (303 mg, 0.94 mmol), TEA (0.28 mL, 2.00 mmol) and EDCI (360 mg, 1.88 mmol) in 10 mL CH<sub>2</sub>Cl<sub>2</sub> afforded 63 mg (17 % yield) of **4k** as a white solid after silica gel flash column chromatography purification (Hex/AcOEt). Mp: 138 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.29 (s, 1H, H6'), 7.74 (d, *J* = 8.0 Hz, 1H, H3'), 7.62 (d, *J* = 7.7 Hz, 1H, H3), 7.54 (t, *J* = 7.8 Hz, 1H, H5'), 7.45 (t, *J* = 7.6 Hz, 1H, H5), 7.11 (t, *J* = 7.0 Hz, 1H, H4'), 7.09 (t, *J* = 6.7 Hz, 1H, H4), 7.01 (d, *J* = 7.7 Hz, 1H, H6), 2.78 (s, 6H, CH<sub>3</sub>), <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 147.5, 146.8, 138.9, 134.0, 132.9, 129.9, 126.9 (q, *J* = 5.1 Hz), 124.29 (q, *J* = 271.5 Hz), 124.3, 124.0, 123.1 (q, *J* = 28.0 Hz), 122.4, 122.1, 37.7. IR (neat, cm<sup>-1</sup>): 1674 (C=N), 1151 (SO<sub>2</sub>). EI-MS *m/z* 386 (M<sup>+</sup>). Elemental analysis for C<sub>16</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S • 0.2 H<sub>2</sub>O calcd: %C, 49.28; %H, 4.39; %N, 14.37; found: %C, 49.62; %H, 4.19, %N, 14.01.

**N-methyl-2-(3-(2-(trifluoromethyl)phenyl)guanidino) benzenesulfonamide (4l).** Following general procedure B, 2-amino-N-methylbenzenesulfonamide hydrochloride (684 mg, 3.07 mmol), **10** (1.00 g, 3.08 mmol), TEA (0.86 mL, 6.18 mmol) and EDCI (1.13 g, 5.88 mmol) in 25 mL CH<sub>2</sub>Cl<sub>2</sub> afforded 326 mg (29 % yield) of **4l** as a white solid after silica gel flash column chromatography purification (CH<sub>2</sub>Cl<sub>2</sub>/MeOH). Mp: 115 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>/MeOD): δ 7.85 (d, *J* = 7.8 Hz, 1H, H3'), 7.65 (d, *J* = 7.8 Hz, 1H, H3), 7.50 (m, 4H, H5, H6, H5', H6'), 7.23 (m, 1H, H4), 7.09 (t, *J* = 7.9 Hz, 1H, H4'), 2.41 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>/MeOD): δ 150.4, 144.3, 140.3, 133.7, 132.6, 129.5, 128.8, 127.1, 126.6 (q, *J* = 5.2 Hz), 124.3, 124.1 (q, *J* = 30.0 Hz), 124.0 (q, *J* = 271.3 Hz), 123.9, 121.9, 29.0. IR (neat, cm<sup>-1</sup>): 1652 (C=N), 1149 (SO<sub>2</sub>). EI-MS *m/z* 372 (M<sup>+</sup>). HRMS (ESI/QTOF) *m/z*: [M+H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S 373.0946; found 373.0965.

## 4.2. Computational methods

**4.2.1. Docking Studies.** Docking computations were done with AutoDock446 with biased grid potentials as previously done for Rac1 14,47 using Rac1 crystal structure (PDBID: 1MH1). The docking cavity included Trp56 and where two hydrogen bond donor biases were placed for Asp 57 oxygen carbonyl atom with a 1 kcal/mol well. Box size was 44x56x64 points with a 0.375 spacing between points. Simulations were performed for 100 runs, and the largest cluster results were kept. The energy was recomputed with unbiased maps to get a better estimation of the free energy of binding.

**4.2.2. Chemoinformatic analysis.** JChem for Excel was used for calculations of the structure-based properties (release 19.26.0.571, 2019, ChemAxon; <http://www.chemaxon.com>). Principal component and additional statistical analysis were performed using OriginPro 2017 (release b9.4.0.220; <http://www.OriginLab.com>).

Recombinant protein purification for in vitro assays. A pProEX HT-Tiam vector was used to express murine Tiam1 (DH/PH domains, residues 1033 to 1406) as a fusion protein with an N-terminal 6xHis tag. A pGex-Rac1b plasmid was used to express human Rac1a as a fusion protein with an N-terminal glutathione S-transferase (GST) tag. Rac1a sequence was subcloned into the expression vector pET28a (Novagen) to express Rac1a as a fusion protein with an N-terminal 6xHis tag. For recombinant protein production, *E. coli* BL21 (DE3) strain carrying the recombinant plasmids were grown at 37 °C in 1 L of Terrific Broth until an optical density at 600 nm of 1.5 was reached before induction with 0.5 mM IPTG. After induction, the culture was grown 16 h at 18 °C for protein expression. Cells were harvested by centrifugation and the

expressed proteins were purified by affinity chromatography using GSTrap or HisTrap columns (GE HealthCare) respectively. Proteins were dialyzed and further purified by size exclusion chromatography using a Superdex 75 Preparative Grade Column (GE Healthcare). Protein concentration was determined spectrophotometrically using its molar extinction coefficient at 280 nm, calculated using the Expasy ProtParam tool.

**4.3. In vitro affinity precipitation of Rac-Tiam.** The inhibitory effect of 4i and 2 compounds was tested in a complex formation assay. His-Tiam (1  $\mu$ g) was incubated with GST-Rac1 (2  $\mu$ g) in the presence 1D-142 (100 and 50  $\mu$ M), 1A-116 (100  $\mu$ M) or in the absence of any compound and 15  $\mu$ L of suspended glutathione-agarose beads. After incubation at 4 °C for 30 min, samples were centrifuged and the supernatants were run in a SDS-PAGE gel. The presence of His-Tiam was detected by anti-His Western blotting.

**4.4. In vitro Rac fluorescent mant-GTP exchange assay.** 200 nM purified His-Rac1-GDP was incubated at 30°C in an exchange buffer (75 mM NaCl, 10 mM MgCl<sub>2</sub>, 20 mM Tris·HCl pH 7.5, 5% DMSO). Increasing concentrations of 1D-142 (100, 200 or 500  $\mu$ M) or 100  $\mu$ M 2 were included in the exchange buffer and incubated for 10 minutes before the addition of 500 nM mant-GTP. The reaction was started by the addition of 200 nM Tiam or the same volume of exchange buffer for the non-catalyzed control reaction. Nucleotide exchange was followed by the fluorescence increase of incorporated mant-GTP. Experiments were performed in an Aminco Bowman Series 2 fluorometer, using 355 nm excitation wavelength and collecting emission at 440 nm every 30 seconds. Rate constants (k) were calculated using single-phase exponential equation ( $f = f_{\text{max}} (1 - e^{-kt})$ ) to fit the fluorescence increase.

**4.5. Cell culture and reagents.** HT29 cells, A549 cells, PC3 cells, MDA-MB-231 cells and A375 cells were all obtained from ATCC (Rockville, MD, USA). HT29 cells, A549 cells, MDA-MB-231 cells and A375 cells were seeded in DMEM medium whereas PC3 cells were grown in RPMI 1640 medium (Gibco, Grand Island, NY, USA). Both media were supplemented with 10% fetal bovine serum (Gibco) and 50 µg/ml gentamicin. Culture cells were maintained in 5% CO<sub>2</sub> atmosphere at 37 °C. All cell lines were authenticated and tested for contamination.

The rabbit polyclonal anti-p65 and anti-IκBα antibodies, and peroxidase-conjugated goat anti-rabbit were obtained from Santa Cruz Biotechnology, USA. Secondary goat anti-rabbit FluoroLink™ Cy™2 antibodies were purchased from GE Healthcare Bio-Sciences, Argentina. Mouse mAb anti-actin and peroxidase-conjugated goat anti-rabbit were purchase from Calbiochem. Recombinant human TNF-α was obtained from PeproTech.

**4.6. Cell proliferation assay.** Cell viability was determined by colourimetric MTT (Sigma-Aldrich Co) assay.<sup>46</sup> Cells were seeded in 96-well plates at a density of 1x10<sup>4</sup> cells/well and solutions containing different concentrations of the tested compounds were added. Each assay was done in triplicate. After 72 h of incubation, MTT solution (5 mg/mL in distilled water) was added to cells in the culture medium and plates were incubated for 2 h at 37 °C. Then, the produced formazan was solubilized by the addition of 0.2 mL ethanol and absorbance values were immediately measured using an ELISA plate reader (Eurogenetics MPR-A 4i) at a test wavelength of 570 nm and a reference wavelength of 630 nm. Results from each treated cell culture were normalized as a percentage of absorbance with respect to untreated controls. The drug concentration required to inhibit cell growth by 50% (IC<sub>50</sub>) was determined from concentration-response curves fitted with GraphPad Prism 6.0 software as previously reported.<sup>47</sup> Results are expressed as the mean ± standard deviation (SD) of three independent experiments.

**4.7. Clonogenic assay.** Study was performed as previously described.<sup>47</sup> A549 cells were seeded in 6-well plates at a density of  $1 \times 10^3$  cells/well and allowed to adhere for 24 h. Then, cells were treated or not with 1D-142 (25 and 50  $\mu\text{M}$ ) in complete media by duplicate. At 24 h, culture medium was replaced with drug-free medium, and cells were grown for additional 7 days until visible colonies appeared. Finally, cells were rinsed with PBS, fixed with 10% formaldehyde for 10 min and stained with 1% crystal violet (20% ethanol in distilled water). Colonies comprising at least 50 cells were scored and the images were recorded with a digital camera.<sup>41</sup>

Analysis of nuclear morphology. Cell nuclear apoptotic morphology was observed by staining with DAPI (Sigma-Aldrich Co) as previously described.<sup>47</sup> A549 cells grown on glass coverslips in 24-well plates were incubated or not with 1D-142 (25 and 50  $\mu\text{M}$ ) for 24 h. After washes with PBS, cells were fixed with methanol for 10 min at  $-20\text{ }^\circ\text{C}$  and stained with DAPI (4  $\mu\text{g}/\text{ml}$  in PBS) for 5 min at room temperature protected from the light. Finally, coverslips were rinsed, mounted and imaged on a fluorescence microscope (Olympus BX51) with a DAPI filter.

Apoptosis was determined according to characteristic nuclear morphology: the presence of apoptotic bodies, nuclear condensation, and fragmentation.<sup>48</sup> Apoptotic cells were counted by NIH ImageJ program.<sup>49</sup>

**4.8. Wound Healing Migration Assay.** Cell migration was evaluated using an in vitro wound healing assay as described.<sup>15</sup> Briefly, A549 cells were grown in 24-well plates until 90% confluence was observed. Subsequently, "scratch" wounds were created by scraping confluent monolayers with a sterile pipette tip. After 48 hour incubation in the presence or absence of 1D-142 ((6.25 and 12.5  $\mu\text{M}$ ), cells were fixed. Pictures were taken at 0 and 48 h using a 10X objective. Ten random micrographs per well were obtained and migration area was quantified

using NISElements 3.0 (Nikon) software. Wound closure measurements were normalized to the maximum scratch area.

**4.9. Indirect immunofluorescence assay (IFI).** The procedure for IFI was performed as previously described.<sup>50</sup> Subconfluent A549 cells grown on glass coverslips in 24-well plates were fixed with methanol for 10min at  $-20^{\circ}\text{C}$ . After three washes with PBS, the coverslips were inverted on a drop of diluted primary antibody for 30 min at  $37^{\circ}\text{C}$ , and then returned to culture dishes and subjected to three additional washes with PBS. Afterwards, cells were incubated with diluted secondary antibody for 30 min at  $37^{\circ}\text{C}$ . Nuclei were counterstained with DAPI ( $4\ \mu\text{g/ml}$  in PBS) for 5 min at room temperature protected from the light. Finally, coverslips were rinsed, mounted and photographed with an Olympus BX51 with epifluorescence optics.

**4.10. Western blot analysis.** Immunoblot procedure was performed as described.<sup>50</sup> Whole extracts from A549 cells grown in 24-well plates were loaded on 10% sodium dodecyl sulphate-polyacrilamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes for 60 min at 75 mA. Membranes were blocked in PBS containing 5% unfitted milk overnight and then incubated with diluted primary antibodies for 2 h at  $37^{\circ}\text{C}$ . After washing, membranes were incubated with diluted peroxidase conjugated antibodies for 1.5 h at  $37^{\circ}\text{C}$ . The immunoreactive bands were visualized using an enhanced chemiluminescence system (ECL, PerkinElmer).

**4.11. In vivo tumor growth and survival studies.** A549 cells were injected subcutaneously ( $2 \times 10^6$  in  $100\ \mu\text{L}$  PBS) into the right posterior leg of male athymic nude mice (nu/nu, 5–6 weeks old). Treatment was initiated when the subcutaneous tumors reached an average size of  $50\ \text{mm}^3$ . Mice were treated every other day with 1D-142 ( $10\ \text{mg/kg/day}$ ) or with vehicle (12.5%

Cremophor EL, 12.5% DMSO as an aqueous suspension) by intra peritoneal injection. Body weight and general health were monitored twice a week. Standard survival criteria were applied including severe lethargy, 20% weight loss, tumor burden  $>2,000 \text{ mm}^3$  and/or difficulty breathing. Survival data was analyzed using GraphPad Prism software. All differences between treatment groups were analyzed by two-way ANOVA.

**4.12. Animal Studies.** All animal studies described here were performed according to approved IACUC protocols and followed University Austral animal care procedures in accordance with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978).

## **AUTHOR CONTRIBUTIONS**

The manuscript was written through contributions of all authors.

## **DECLARATION OF COMPETING INTEREST**

The authors declare no conflict of interest.

## **ACKNOWLEDGMENT**

This work was partly supported by Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) - Fondo para la Investigación Científica y Tecnológica (FONCyT) PICT-201-0362 to

MJC and PICT-2018-1036 to JB, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) PIP2014-2016 to MJC) and by Instituto Nacional de Tecnología Industrial (INTI).

## ABBREVIATIONS

TNF $\alpha$ , tumor necrosis factor alpha; NF- $\kappa$ B, Nuclear factor kappa-light-chain-enhancer of activated B cells; NSCLC, non-small cell lung cancer; PPI, protein-protein interaction; PCA, principal component analysis; EDCI, N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; TEA, triethylamine; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DAPI, 4',6-diamidino phenylindole; GST, glutathione S-transferase; DMSO, dimethyl sulfoxide; TLC, thin layer chromatography.

## APPENDIX A. SUPPLEMENTARY DATA

NMR spectra and chemoinformatic analysis of synthesized compounds. Docking binding mode for compound **4i**/1D-142. Decomposition of predicted Free Energy of Binding for **4i**/1D-142 and 1A-116. Uncropped Western Blots. Supplementary data associated with this article can be found in the online version.

## REFERENCES

- (1) Heasman, S. J.; Ridley, A. J. Mammalian Rho GTPases: New Insights into Their Functions from in Vivo Studies. *Nat. Rev. Mol. Cell Biol.* **2008**, *9* (9), 690–701.
- (2) Kazanietz, M. G.; Caloca, M. J. The Rac GTPase in Cancer : From Old Concepts to New



Paradigms. *Cancer Research* **2017**, 5445–5452.

- (3) Casado-Medrano, V.; Baker, M. J.; Lopez-Haber, C.; Cooke, M.; Wang, S.; Caloca, M. J.; Kazanietz, M. G. The Role of Rac in Tumor Susceptibility and Disease Progression: From Biochemistry to the Clinic. *Biochem. Soc. Trans.* **2018**, *46* (4).
- (4) Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The next Generation. *Cell* **2011**, *144* (5), 646–674.
- (5) Hodge, R. G.; Ridley, A. J. Regulating Rho GTPases and Their Regulators. *Nat. Rev. Mol. Cell Biol.* **2016**, *17* (8), 496–510.
- (6) A.P. Porter, A. Papaioannou, A. M. Deregulation of Rho GTPases in Cancer. *Small GTPases* **2016**, *7* (3), 123–138.
- (7) Zhou, Y.; Liao, Q.; Han, Y.; Chen, J.; Liu, Z.; Ling, H.; Zhang, J.; Yang, W.; Oyang, L.; Xia, L.; Wang, L.; Wang, H.; Xue, L.; Wang, H.; Hu, B. Rac1 Overexpression Is Correlated with Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Non-Small Cell Lung Cancer. *J. Cancer* **2016**, *7* (14), 2100–2109.
- (8) Krauthammer, M.; Kong, Y.; Ha, B. H.; Evans, P.; Bacchiocchi, A.; McCusker, J. P.; Cheng, E.; Davis, M. J.; Goh, G.; Choi, M.; Ariyan, S.; Narayan, D.; Dutton-Regester, K.; Capatana, A.; Holman, E. C.; Bosenberg, M.; Sznol, M.; Kluger, H. M.; Brash, D. E.; Stern, D. F.; Materin, M. A.; Lo, R. S.; Mane, S.; Ma, S.; Kidd, K. K.; Hayward, N. K.; Lifton, R. P.; Schlessinger, J.; Boggon, T. J.; Halaban, R. Exome Sequencing Identifies Recurrent Somatic RAC1 Mutations in Melanoma. *Nat. Genet.* **2012**, *44* (9), 1006–1014.
- (9) Zou, T.; Mao, X.; Yin, J.; Li, X.; Chen, J.; Zhu, T.; Li, Q.; Zhou, H.; Liu, Z. Emerging Roles

- of RAC1 in Treating Lung Cancer Patients. *Clin. Genet.* **2017**, *91* (4), 520–528.
- (10) Zhu, G.; Fan, Z.; Ding, M.; Zhang, H.; Mu, L.; Ding, Y.; Zhang, Y.; Jia, B.; Chen, L.; Chang, Z.; Wu, W. An EGFR/PI3K/AKT Axis Promotes Accumulation of the Rac1-GEF Tiam1 That Is Critical in EGFR-Driven Tumorigenesis. *Oncogene* **2015**, *34* (49), 5971–5982.
- (11) Vigil, D.; Cherfils, J.; Rossman, K. L.; Der, C. J. Ras Superfamily GEFs and GAPs: Validated and Tractable Targets for Cancer Therapy? *Nat. Rev. Cancer* **2010**, *10* (12), 842–857.
- (12) Traut, T. W. Physiological Concentrations of Purines and Pyrimidines I. *Mol. Cell. Biochem.* **1994**, *140*, 1–22.
- (13) Gray, J. L.; Delft, F. Von; Brennan, P. E. Targeting the Small GTPase Superfamily through Their Regulatory Proteins Angewandte Reviews. *Angew. Chemie Int. Ed.* **2020**, *59*, 6342–6366.
- (14) Ding, J.; Yang, F.; Wu, W. F. Tiam1 High Expression Is Associated with Poor Prognosis in Solid Cancers: A Meta-Analysis. *Medicine (Baltimore)*. **2019**, *98* (45), e17529.
- (15) Cardama, G. A.; Comin, M. J.; Hornos, L.; Gonzalez, N.; Defelipe, L.; Turjanski, G.; Alonso, D. F.; Gomez, D. E.; Menna, P. L. Preclinical Development of Novel Rac1-GEF Signaling Inhibitors Using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines. *Anticancer Agents Med. Chem.* **2014**, *14* (6), 840–851.
- (16) Gao, Y.; Dickerson, J. B.; Guo, F.; Zheng, J.; Zheng, Y. Rational Design and Characterization of a Rac GTPase-Specific Small Molecule Inhibitor. *Proc. Natl. Acad. Sci.*

*U. S. A.* **2004**, *101* (20), 7618–7623.

- (17) Ferri, N.; Corsini, A.; Bottino, P.; Clerici, F.; Contini, A. Virtual Screening Approach for the Identification of New Rac1 Inhibitors. *J. Med. Chem.* **2009**, *52* (14), 4087–4090.
- (18) Montalvo-Ortiz, B. L.; Castillo-Pichardo, L.; Hernández, E.; Humphries-Bickley, T.; De la Mota-Peynado, A.; Cubano, L. a; Vlaar, C. P.; Dharmawardhane, S. Characterization of EHop-016, Novel Small Molecule Inhibitor of Rac GTPase. *J. Biol. Chem.* **2012**, *287* (16), 13228–13238.
- (19) Colomba, A.; Giuriato, S.; Dejean, E.; Thornber, K.; Delsol, G.; Tronchère, H.; Meggetto, F.; Payrastre, B.; Gaits-Iacovoni, F. Inhibition of Rac Controls NPM-ALK-Dependent Lymphoma Development and Dissemination. *Blood Cancer J.* **2011**, *1* (6), 1–7.
- (20) Karpel-Massler, G.; Westhoff, M. A.; Zhou, S.; Nonnenmacher, L.; Dwucet, A.; Kast, R. E.; Bachem, M. G.; Wirtz, C. R.; Debatin, K. M.; Halatsch, M. E. Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells. *Mol. Cancer Ther.* **2013**, *12* (9), 1783–1795.
- (21) Yoshida, T.; Zhang, Y.; Rivera Rosado, L. A.; Chen, J.; Khan, T.; Moon, S. Y.; Zhang, B. Blockade of Rac1 Activity Induces G1 Cell Cycle Arrest or Apoptosis in Breast Cancer Cells through Downregulation of Cyclin D1, Survivin, and X-Linked Inhibitor of Apoptosis Protein. *Mol. Cancer Ther.* **2010**, *9* (6), 1657–1668.
- (22) Dütting, S.; Heidenreich, J.; Cherpokova, D.; Amin, E.; Zhang, S. C.; Ahmadian, M. R.; Brakebusch, C.; Nieswandt, B. Critical Off-Target Effects of the Widely Used Rac1

- Inhibitors NSC23766 and EHT1864 in Mouse Platelets. *J. Thromb. Haemost.* **2015**, *13* (5), 827–838.
- (23) Ferri, N.; Bernini, S. K.; Corsini, A.; Clerici, F.; Erba, E.; Stragliotto, S.; Contini, A. 3-Aryl-N-Aminoylsulfonylphenyl-1H-Pyrazole-5-Carboxamides: A New Class of Selective Rac Inhibitors. *Medchemcomm* **2013**, *4* (3), 537–541.
- (24) Humphries-Bickley, T.; Castillo-Pichardo, L.; Corujo-Carro, F.; Duconge, J.; Hernandez-O’Farrill, E.; Vlaar, C.; Rodriguez-Orengo, J. F.; Cubano, L.; Dharmawardhane, S. Pharmacokinetics of Rac Inhibitor EHop-016 in Mice by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2015**, *981–982*, 19–26.
- (25) Cubano, L. A.; Rodriguez-Medina, J. R.; Hernandez-O-Farrill, E.; Borrero-Garcia, L. D.; Blanco, M.; Rivera-Robles, M. J.; Forestier-Roman, I.; Dharmawardhane, S.; Gerena, Y.; Humphries-Bickley, T.; Vlaar, C. P.; Castillo-Pichardo, L. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. *Mol. Cancer Ther.* **2017**, *16* (5), 805–818.
- (26) Gao, Y.; Xing, J.; Streuli, M.; Leto, T. L.; Zheng, Y. Trp(56) of Rac1 Specifies Interaction with a Subset of Guanine Nucleotide Exchange Factors. *J. Biol. Chem.* **2001**, *276* (50), 47530–47541.
- (27) Lorenzano Menna, P.; Alonso, D.; Gomez, D.; Comin, M. Phenyl-guanidine Derivatives. WO2013053726 (A1) -, 2012.
- (28) Cardama, G. A.; Gonzales, N.; Ciarlantini, M.; Donadío, L. G.; Comin, M. J.; Alonso, D.

- F.; Menna, P. L.; Gomez, D. E. Proapoptotic and Antiinvasive Activity of Rac1 Small Molecule Inhibitors on Malignant Glioma Cells. *Onco. Targets. Ther.* **2014**, *7*, 2021–2033.
- (29) Cabrera, M.; Echeverria, E.; Lenicov, F. R.; Cardama, G.; Gonzalez, N.; Davio, C.; Fernández, N.; Lorenzano Menna, P. Pharmacological Rac1 Inhibitors with Selective Apoptotic Activity in Human Acute Leukemic Cell Lines. **2017**, *8*, 98509–98523.
- (30) Gonzalez, N.; Cardama, G. A.; Comin, M. J.; Segatori, V. I.; Pifano, M.; Alonso, D. F.; Gomez, D. E.; Menna, P. L. Pharmacological Inhibition of Rac1-PAK1 Axis Restores Tamoxifen Sensitivity in Human Resistant Breast Cancer Cells. *Cell. Signal.* **2017**, *30*, 154–161.
- (31) Wenderski, T. A.; Stratton, C. F.; Bauer, R. A.; Kopp, F.; Tan, D. S. Principal Component Analysis as a Tool for Library Design: A Case Study Investigating Natural Products, Brand-Name Drugs, Natural Product-like Libraries, and Drug-like Libraries. In *Chemical Biology: Methods and Protocols*; Hempel, J. E., Williams, C. H., Hong, C. C., Eds.; 2015; Vol. 46, pp 225–242.
- (32) Stratton, C. F.; Newman, D. J.; Tan, D. S. Cheminformatic Comparison of Approved Drugs from Natural Product versus Synthetic Origins. *Bioorganic Med. Chem. Lett.* **2015**, *25* (21), 4802–4807.
- (33) Katritzky, A. R.; Rogovoy, B. V. Recent Developments in Guanylyating Agents. *Arkivok* **2005**, *iv*, 49–87.
- (34) Moustafa, A. H.; Ahmed, W. W.; Khodairy, A. Syntheses of Some New N-Linked Pyrimidine-2-Amines with Pyrazinopyrimidines, Thienopyrimidines, and Benzazoles via

- Reactions of Various Nucleophiles with Cyanamides. *J. Heterocycl. Chem.* **2017**, *54* (6), 3490–3497.
- (35) Foussard-Blanpin, O.; Uchida-Ernouf, G.; Anatol, J.; Berecoechea, J. Acylcyanamides, Acylurée, Aryl Allophanates D'éthyle Diversement Substitués; Action Sur Le System Nerveux Central. *Eur. J. Med. Chem.* **1979**, *14* (3), 215–218.
- (36) Linton, B. R.; Carr, A. J.; Orner, B. P.; Hamilton, A. D. A Versatile One-Pot Synthesis of 1, 3-Substituted Guanidines from Carbamoyl Isothiocyanates. *J. Org. Chem.* **2000**, *65* (5), 1566–1568.
- (37) Zhang, J.; Shi, Y.; Stein, P.; Atwal, K.; Li, C. One-Pot Synthesis of N, N'-Disubstituted Acylguanidines. *Tetrahedron Lett.* **2002**, *43*, 57–59.
- (38) Worthyake, D. K.; Rossman, K. L.; Sondek, J. Crystal Structure of Rac1 in Complex with the Guanine Nucleotide Exchange Region of Tiam1. *Nature* **2000**, *408* (6813), 682–688.
- (39) Zhang, T.; Wang, N. MiR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1. *Oncol. Res.* **2018**, *26* (8), 1191–1200.
- (40) Kaneto, N.; Yokoyama, S.; Hayakawa, Y.; Kato, S.; Sakurai, H.; Saiki, I. RAC1 Inhibition as a Therapeutic Target for Gefitinib-Resistant Non-Small-Cell Lung Cancer. *Cancer Sci.* **2014**, *105* (7), 788–794.
- (41) Franken, N. A. P.; Rodermond, H. M.; Stap, J.; Haveman, J.; Bree, C. Van. Clonogenic Assay of Cells in Vitro. *Nat. Protoc.* **2006**, *1* (5), 2315–2319.
- (42) Gastonguay, A.; Berg, T.; Hauser, A.; Schuld, N.; Lorimer, E.; Willimas, C. The Role of Rac1 in the Regulation of NFκB Activity, Cell Proliferation and Cell Migration in Non-

Small Cell Lung Carcinoma. *Cancer Biol. Ther.* **2012**, *13* (8), 647–656.

- (43) Hayden, M. S.; Ghosh, S. Shared Principles in NF-KB Signaling. *Cell* **2008**, *132* (3), 344–362.
- (44) <http://zinc15.docking.org/patterns/home/>.
- (45) Rauf, M. K.; Talib, A.; Badshah, A.; Zaib, S.; Shoaib, K.; Shahid, M.; Flörke, U.; Imtiaz-Ud-Din; Iqbal, J. Solution-Phase Microwave Assisted Parallel Synthesis of N,N'-Disubstituted Thioureas Derived from Benzoic Acid: Biological Evaluation and Molecular Docking Studies. *Eur. J. Med. Chem.* **2013**, *70*, 487–496.
- (46) Denizot, F.; Lang, R. Rapid Colorimetric Assay for Cell Growth and Survival. Modifications to the Tetrazolium Dye Procedure Giving Improved Sensitivity and Reliability. *J. Immunol. Methods* **1986**, *89* (2), 271–277.
- (47) Alonso, F.; Quezada, M. J.; Gola, G. F.; Richmond, V.; Cabrera, G. M.; Barquero, A. A.; Ramírez, J. A. A Minimalist Approach to the Design of Complexity-Enriched Bioactive Small Molecules: Discovery of Phenanthrenoid Mimics as Antiproliferative Agents. *ChemMedChem* **2018**, *13* (16), 1732–1740.
- (48) Sawai, Y.; Murata, H.; Horii, M.; Koto, K.; Matsui, T.; Horie, N.; Tsuji, Y.; Ashihara, E.; Maekawa, T.; Kubo, T.; Fushiki, S. Effectiveness of Sulforaphane as a Radiosensitizer for Murine Osteosarcoma Cells. *Oncol. Rep.* **2013**, *29* (3), 941–945.
- (49) NIH ImageJ program: <https://imagej.net/Welcome>.

- (50) Bueno, C. A.; Barquero, A. A.; Di Cónsoli, H.; Maier, M. S.; Alché, L. E. A Natural Tetranortriterpenoid with Immunomodulating Properties as a Potential Anti-HSV Agent. *Virus Res.* **2009**, *141* (1), 47–54.